Wheeldon TU et al. |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15191514
|
Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Romero-Gómez M et al. |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616169
|
Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Perri F et al. |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421878
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421879
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Gatta L et al. |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963079
|
Kamada T et al. |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12869086
|
Lamouliatte H et al. |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535872
|
Miehlke S et al. |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535873
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Gisbert JP et al. |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10540045
|
Peterson WL |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146787
|
Sierra F et al. |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23656465
|
Di Mario F et al. |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16611285
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Borody TJ et al. |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441468
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Chan FK et al. |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632651
|
Pipkin GA et al. |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768524
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Louw JA et al. |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768531
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Di Caro S et al. |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876707
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Wu JC et al. |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876709
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
Savarino V et al. |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:9892878
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
Bazzoli F et al. |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663723
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Goh KL et al. |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663838
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Kolkman JJ et al. |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663840
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Laurent J et al. |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683693
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Gené E et al. |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752350
|
Sheu BS et al. |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755841
|
You JH et al. |
Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421876
|
Cammarota G et al. |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971300
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971305
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
Cammarota G et al. |
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15043520
|
Vcev A et al. |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632647
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Pilotto A and Malfertheiner P |
Review article: an approach to Helicobacter pylori infection in the elderly. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929385
|
Osato MS et al. |
Comparative efficacy of new investigational agents against Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284777
|
Xiao SD et al. |
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11136281
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
Wong WM et al. |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423001
|
Jung YS et al. |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28497487
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Isomoto H et al. |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848631
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Lim AG et al. |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218079
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Savarino V et al. |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886045
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Chen PY et al. |
Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074519
|
McNulty CA et al. |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22469191
|